日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Declining anthropogenic aerosols amplify Northern Hemisphere Hadley circulation weakening in the 21st century

21世纪人为气溶胶的减少加剧了北半球哈德莱环流的减弱。

Kim, S-Y; Son, S-W; Ming, Y; Hong, D-C; Gu, Xihui; Park, R J

Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer

拉罗替尼作为TRK融合癌患者一线治疗的疗效和安全性

Hong, D S; Xu, R-H; Shen, L; Dierselhuis, M P; Orbach, D; McDermott, R; Italiano, A; Tahara, M; Bernard-Gauthier, V; Neu, N; Mussi, C E; De La Cuesta, E; Laetsch, T W; Drilon, A

Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors

利用自身抗体谱预测罕见肿瘤患者对PD-1抑制剂帕博利珠单抗的反应

Derbala, M H; Hajjar, J; Stephen, B; Gurses, S A; Kwiatkowski, E; Budde, P; Zucht, H-D; Bräutigam, M; Lindemann, A-S; Abhari, B A; Gouda, M A; Castillo, L; Zarifa, A; How, J A; Rodriguez, E; Moyers, J T; Hong, D S; Fu, S; Meric-Bernstam, F; Naing, A

The impact of preoperative stoma education on postoperative outcomes for patients with new stomas after colorectal surgery: a systematic review and meta-analysis

术前造口教育对结直肠手术后新造口患者术后结局的影响:系统评价和荟萃分析

Shi, V; McKechnie, T; Anant, S; Pedroso, C M; Ahmed, M; Patel, J; Sharma, S; Talwar, G; Hong, D; Eskicioglu, C

A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors

TAK-659 和紫杉醇治疗紫杉烷类耐药晚期实体瘤患者的 I 期研究

Gouda, M A; Shunyakova, J; Naing, A; Dumbrava, E; Hong, D S; Yuan, Y; Yang, P; Myers, A; Liang, Y; Peng, J; Karp, D; Tsimberidou, A M; Rodon, J; Yap, T A; Piha-Paul, S A; Meric-Bernstam, F; Fu, S

Evaluation of Selected Markers in Kidneys of Cynomolgus Monkey (Macaca fascicularis) with Induced Diabetes during Renal Ischemia-reperfusion Injury

糖尿病食蟹猴(Macaca fascicularis)肾脏缺血再灌注损伤过程中选择性标志物的评估

Tae M Kim, Kyo W Lee, Hong D Kim, Sung O Hong, Hye J Cho, Je H Yang, Sung J Kim, Jae B Park

Epidemiology of resistance of carbapenemase-producing Klebsiella pneumoniae to ceftazidime-avibactam in a Chinese hospital

中国某医院产碳青霉烯酶肺炎克雷伯菌对头孢他啶-阿维巴坦耐药性的流行病学研究

Chen, D; Xiao, L; Hong, D; Zhao, Y; Hu, X; Shi, S; Chen, F

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

凡德他尼联合依维莫司治疗晚期实体瘤患者的安全性和疗效:一项 I 期研究

Cascone, T; Sacks, R L; Subbiah, I M; Drobnitzky, N; Piha-Paul, S A; Hong, D S; Hess, K R; Amini, B; Bhatt, T; Fu, S; Naing, A; Janku, F; Karp, D; Falchook, G S; Conley, A P; Sherman, S I; Meric-Bernstam, F; Ryan, A J; Heymach, J V; Subbiah, V

Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications

在不考虑肿瘤类型的适应症中,恩曲替尼单臂试验的患者内疗效比较

Krebs, M G; Blay, J-Y; Le Tourneau, C; Hong, D; Veronese, L; Antoniou, M; Bennett, I

PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers

血浆循环肿瘤DNA中的PIK3CA突变可预测晚期癌症患者的生存期和治疗结果。

Dumbrava, E E; Call, S G; Huang, H J; Stuckett, A L; Madwani, K; Adat, A; Hong, D S; Piha-Paul, S A; Subbiah, V; Karp, D D; Fu, S; Naing, A; Tsimberidou, A M; Moulder, S L; Koenig, K H; Barcenas, C H; Kee, B K; Fogelman, D R; Kopetz, E S; Meric-Bernstam, F; Janku, F